These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 34213646)
1. A new era for people with cystic fibrosis. Bierlaagh MC; Muilwijk D; Beekman JM; van der Ent CK Eur J Pediatr; 2021 Sep; 180(9):2731-2739. PubMed ID: 34213646 [TBL] [Abstract][Full Text] [Related]
2. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
3. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364 [TBL] [Abstract][Full Text] [Related]
4. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis. Mayer-Hamblett N; Boyle M; VanDevanter D Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594 [TBL] [Abstract][Full Text] [Related]
5. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator. Ong T; Ramsey BW Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186 [TBL] [Abstract][Full Text] [Related]
6. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update. Egan ME Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578 [TBL] [Abstract][Full Text] [Related]
7. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
8. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation. Caverly LJ; Riquelme SA; Hisert KB Clin Chest Med; 2022 Dec; 43(4):647-665. PubMed ID: 36344072 [TBL] [Abstract][Full Text] [Related]
10. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
12. Entering the era of highly effective modulator therapies. Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412 [TBL] [Abstract][Full Text] [Related]
13. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis. Taylor-Cousar JL; Shteinberg M; Cohen-Cymberknoh M; Jain R Clin Ther; 2023 Mar; 45(3):278-289. PubMed ID: 36841738 [TBL] [Abstract][Full Text] [Related]
14. New treatments targeting the basic defects in cystic fibrosis. Fajac I; Wainwright CE Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723 [TBL] [Abstract][Full Text] [Related]
15. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis. Cuyx S; De Boeck K Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727 [TBL] [Abstract][Full Text] [Related]
16. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators. Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261 [TBL] [Abstract][Full Text] [Related]
17. CFTR modulator therapies - Effect on life expectancy in people with cystic fibrosis. Balfour-Lynn IM; King JA Paediatr Respir Rev; 2022 Jun; 42():3-8. PubMed ID: 32565113 [TBL] [Abstract][Full Text] [Related]
18. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Bulloch MN; Hanna C; Giovane R Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346 [TBL] [Abstract][Full Text] [Related]
19. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant. Mitchell RM; Jones AM; Barry PJ Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080 [TBL] [Abstract][Full Text] [Related]
20. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]